Stocks/GENB

GENB

Generate Biomedicines, Inc.
Financial Services·Asset Management
$13.12
$1.7B market cap
Revenue
$7.2M
Free Cash Flow
$-84.2M
Rev Growth
+0.0%
FCF Margin
-1165.1%
P/FCF
--
EV/FCF
--
Fwd EV/EBITDA
--
Fair Value
--
Upside
--

Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States. It uses protein-based modalities for drug development. Its product includes GB-0895, is an investigational long-acting anti-TSLP monoclonal antibody in development for severe asthma that is intended to be dosed every six months; GB-4362, an MMAE payload neutralizer monoclonal antibody; GB-5

2-Year Price History

$14.53+14.9%
$12$13$14$15$16volFeb 26Mar 26Mar 26Apr 26Apr 26May 26May 26

Quarterly Financials & Projections

Quarterly Waterfall ($ M)
PeriodRevEBITDAOpInNIOCFFCFCapExCashDebtSharesROICIntCovEV/EBITDA
Act2026-Q17.2-60.8-64.1-61.5-80.4-84.2-3.8516.665.6128.2-55.1%-334.3x--

Valuation & Metrics

Market Stats

Price$13.12
Market Cap$1.7B
Enterprise Value$1.2B
P/S Ratio232.8x
P/FCF--
EV/FCF--
FCF Margin (TTM)-1165.1%
FCF Yield-5.0%
Dividend Yield (TTM)--
Annual Dilution0.0%
CurrencyUSD

TTM Financial Snapshot

Revenue$7.2M
Net Income$-61.5M
Free Cash Flow$-84.2M

Revenue Growth (YoY)+0.0%
EBITDA Margin-842.2%
Net Margin-850.6%
FCF Margin-1165.1%
CapEx % of Revenue52.3%
SBC % of Revenue0.0%
ROIC-55.1%
WC Change % Rev0.0%
Interest Coverage-334.3x

Forward Outlook & Risk

Short Interest

Short % of Float--
Short Shares3.2M
Days to Cover9.7
Change (vs Prior)+53.0%
Need at least 2 settlement dates for chart

Employees

Headcount312
Revenue / Employee$23,154
Gross Profit / Employee$12,663

Institutional Ownership

Headline & net flow

NEUTRAL
Net flow · still filing
No float data — flow unavailable.

Ownership composition

Active
66.1%
51 filers
hedge / family / endowment
Retail funds
Fidelity, Schwab, 401(k)
Passive
0.2%
4 filers
Vanguard, iShares, SPDR
Market makers
0.1%
2 filers
Citadel, Susquehanna
Insiders
Form 4 — latest per insider
Not enough quarterly ownership history to chart yet.

Top holders

Fund$ valueCost basisΔ QoQΔ YoYα lifeFund AUM
Flagship Pioneering Inc.$783M$12.50+$783M+$783M$1.16B
FMR LLC$52.7M$12.50+$52.7M+$52.7M$1.89T
Capital World Investors$50.1M$12.50+$50.1M+$50.1M$732.46B
BRAIDWELL LP$44.9M$12.50+$44.9M+$44.9M$2.63B
JPMORGAN CHASE & CO$33.9M$12.50+$36.8M+$33.9M$1.47T
PRICE T ROWE ASSOCIATES INC /MD/$26.4M$12.50+$26.4M+$26.4M$864.93B
ARCH Venture Management, LLC$24.3M$12.50+$24.3M+$24.3M$677M
HARBOURVEST PARTNERS LLC$21.5M$12.50+$21.5M+$21.5M$101M
BAKER BROS. ADVISORS LP$17.8M$12.50+$17.8M+$17.8M$16.13B
HARVARD MANAGEMENT CO INC$13.9M$12.50+$13.9M+$13.9M$1.82B
NVIDIA CORP$10.4M$12.50+$10.4M+$10.4M$18.37B
Siren, L.L.C.$9.2M$12.50+$9.2M+$9.2M$3.61B
Davern Capital Partners, LP$7.4M$12.50+$7.4M+$7.4M$335M
Alyeska Investment Group, L.P.$6.3M$12.50+$6.3M+$6.3M$35.33B
ARK Investment Management LLC$6.2M$12.50+$6.2M+$6.2M$12.86B
MILLENNIUM MANAGEMENT LLC$4.7M$12.50+$4.7M+$4.7M$127.40B
UBS Group AG$4.5M$12.50+$4.5M+$4.5M$562.11B
Affinity Asset Advisors, LLC$4.4M$12.50+$4.4M+$4.4M$1.60B
MORGAN STANLEY$4.2M$12.50+$4.2M+$4.2M$1.65T
ExodusPoint Capital Management, LP$3.9M$12.50+$3.9M+$3.9M$10.04B
Cost basis is a volume-weighted estimate from accumulation periods within our 13F history; holders who built their position before our window started will show a stale basis. % above the cost basis is the unrealized gain at the current price.

Trading behavior

Smart-money alpha (lifetime, %/qtr)BEARISH
Holders
-9.20%
avg per quarter
Holders (ex-self)
excl. this stock
Buyers (this Q)
-9.20%
57 buyers · $1.16B in
Sellers (this Q)
+0.00%
0 sellers · $0.00B out
alpha coverage: 100% of $ has a lifetime-alpha record
Holder behavior (holder profile)source: holder
On big dips (−10%+)
-2.1%
how holders react when this stock falls
On quiet Qs
-1.0%
−10% to +10% baseline
On rallies (+10%+)
-5.3%
how they react when this stock rises
Holders' portfolio flow this Q
+164.0%
inflows — adds are organic
Sellers' portfolio flow this Q
+0.0%
Sellers' overall flow ~ flat.

Top Holders Over Time

5-year share-count history (top 10 holders by peak, incl. exited) + price

Not enough holder history to plot.

Analyst Coverage

Analyst Coverage
Price Targets
Last Quarter (2 analysts)$23.507910.0%
Last Year (2 analysts)$23.507910.0%
Current Price$13.12
Analyst Ratings
2
Buy: 2Consensus: Buy

Corporate

Order Flow (FINRA, ~3w lag)

22.6%retail+6.2pp
28.7%dark+0.8pp
week of 2026-04-13
10%15%20%25%30%26-0226-0326-0326-0326-0326-0326-0426-04retail (non-ATS)dark (ATS)
Off-exchange volume from FINRA. Retail = non-ATS (wholesaler PFOF + broker internalization). Dark = ATS (dark-pool crossing networks, institutional). Lit-exchange = remainder.